spacer
home > ebr > spring 2017 > just value
PUBLICATIONS
European Biopharmaceutical Review

Just Value

Aristotle pondered the relationship between price and value in economic exchange. Healthcare systems are coming to grips with rising product costs by experimenting with valuebased contracts. They are attempting to ensure an incentive for innovation while establishing a relationship between prices and clinical outcomes.

Healthcare expenses are again rising dramatically. Even though drugs account for only 10% of costs, the subject of pricing still grabs attention and this, in turn, has become political fodder. Both intentional and unintentional comments by politicians and payers have whipsawed the share prices of pharmaceutical stocks.

A decade ago, drug price increases had moderated as the effects of the ‘patent cliff’ were felt, and many blockbusters went generic. Recently, we have witnessed an uptick in the rate of drug expenditures attributed to more approvals – often speciality products and a slowdown in the shift to generics. However, speciality pharmaceuticals are a particularly important cost driver – they accounted for one third of all drug expenditures in a 2014 study, yet they represent less than 1% of written prescriptions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Data at ASH 2016 Show Strong, Lasting Efficacy of Imbruvica® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukaemia (CLL)


More info >>

White Papers

Choosing the Right CMO for HPAPI Manufacturing

AMRI

Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

 
Industry Events

11th Pharmaceutical Logistics

18-19 May 2017, Copthorne Tara Hotel, London, UK

As outsourcing logistical tasks continues to be an emerging lucrative trend within the pharma industry, SMi Group proudly announces the return of its 11th annual Pharmaceutical Logistics event to London on 18-19th May 2017. Registration is now live on www.pharmaceutical-logistics.om/samedan.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement